Vertigo Care Revolution: Vertigenius Fuels US Expansion with New Funding
April 9, 2026, 9:34 pm
Vertigenius, a MedTech leader, secured €2.55M ($3M) funding, fueling its rapid US expansion. Their remote monitoring platform transforms vertigo care. It uses a smart head sensor and patient app, feeding real-time data to clinicians. This innovative system tracks home rehabilitation exercises, boosts patient adherence, and refines treatment plans. It eases clinic burdens and slashes wait times for vestibular therapy. US clinics access new remote monitoring reimbursement. Launched last October, the platform already serves nearly 3,000 patients across 11 US states. Vertigenius targets a €3 billion US market, planning future global growth. New hires support R&D and commercial scaling.
Vertigenius, an Irish MedTech innovator, secured significant new funding. A €2.55 million ($3 million) round will drive its ambitious US market expansion. This investment, totaling over $5 million to date, marks a pivotal moment. The company focuses on transforming vestibular care across the globe.
Vertigo afflicts millions. Around 390 million people worldwide experience this debilitating condition. Dizziness and imbalance are common symptoms. Traditional rehabilitation relies on clinic visits. Patients complete most exercises at home. Clinicians previously lacked objective insight into this home therapy. They could not monitor adherence or progress remotely. This created significant gaps in care delivery. It often led to suboptimal outcomes. Patient engagement suffered without immediate feedback.
Vertigenius developed a unique solution. It offers a comprehensive vestibular rehabilitation platform. The system combines a wearable head sensor, a patient smartphone application, and a dedicated clinician portal. This integrated approach bridges the gap in remote monitoring. It tracks patient adherence to prescribed home exercises.
The behind-the-ear head sensor detects 3D head movement. It monitors specific exercise performance in real time. The patient app provides guided cues. It helps users perform movements correctly. Patients also track their symptoms directly in the app. All this vital data streams to the clinician portal. Providers gain clinically relevant insights. They proactively tailor treatments. This significantly elevates the standard of patient care.
The platform accelerates clinician workflows. It significantly reduces the administrative burden. It decreases the number of required clinic visits. This eases critically long waiting lists for vestibular therapists. It supports overstretched healthcare teams globally. Patients benefit from continuous feedback and personalized adjustments. This direct communication fosters improved adherence. It leads to better treatment outcomes. Successful vestibular rehabilitation depends on consistent, accurate effort between visits. Vertigenius precisely enables this crucial aspect of recovery.
The United States represents a lucrative market. It has an addressable market exceeding €3 billion. Over 5,000 vestibular clinics operate nationwide. Vertigenius launched commercially in the US last October. It secured FDA registration prior to launch. Early adoption is strong. Twenty clinics in 11 US states use the device. These clinics have treated nearly 3,000 patients combined.
A key driver in the US is insurance reimbursement. Clinics can access additional income streams. This comes from remote therapeutic monitoring (RTM) codes. Vertigenius is specifically designed for RTM workflows. It captures vital non-physiological data. This includes detailed exercise adherence logs. It also records patient-reported symptoms. This comprehensive data supports RTM documentation and subsequent claims. It opens previously unavailable revenue opportunities for providers. This makes the platform financially attractive for US clinics.
The recent funding round was led by Atlantic Bridge. Enterprise Ireland and several venture firms also supported it. This follows a €2.1 million fundraising round in 2024. The new capital will scale US commercial operations. It will advance product development. The focus includes clinician workflow acceleration. Patient adherence improvements are also a priority.
Vertigenius will expand its US commercial team. New hires are planned for Ireland. These roles span clinical research, product R&D, quality assurance, and regulatory affairs. All new hires will operate from the company's Irish headquarters. The company anticipates further expansion. Europe is next. Then Asia Pacific and other global markets. Vertigenius aims to transform vertigo treatment worldwide.
Vertigenius addresses a significant, unmet clinical need. It targets a multi-billion-dollar market. Its unique platform fundamentally enhances vestibular care delivery. It continuously connects clinicians and patients. This vital support bridges the gap between visits. The early traction in the US validates the platform's clinical efficacy. It confirms the substantial commercial opportunity. The company actively recruits early adopter clinics and health systems. Its Lighthouse Site Program offers comprehensive onboarding and support. Participants contribute structured feedback. They may also join case studies and educational programs. Vertigenius is poised for substantial, transformative growth. It promises a new era in remote vertigo care management.
Vertigenius, an Irish MedTech innovator, secured significant new funding. A €2.55 million ($3 million) round will drive its ambitious US market expansion. This investment, totaling over $5 million to date, marks a pivotal moment. The company focuses on transforming vestibular care across the globe.
Vertigo afflicts millions. Around 390 million people worldwide experience this debilitating condition. Dizziness and imbalance are common symptoms. Traditional rehabilitation relies on clinic visits. Patients complete most exercises at home. Clinicians previously lacked objective insight into this home therapy. They could not monitor adherence or progress remotely. This created significant gaps in care delivery. It often led to suboptimal outcomes. Patient engagement suffered without immediate feedback.
Vertigenius developed a unique solution. It offers a comprehensive vestibular rehabilitation platform. The system combines a wearable head sensor, a patient smartphone application, and a dedicated clinician portal. This integrated approach bridges the gap in remote monitoring. It tracks patient adherence to prescribed home exercises.
The behind-the-ear head sensor detects 3D head movement. It monitors specific exercise performance in real time. The patient app provides guided cues. It helps users perform movements correctly. Patients also track their symptoms directly in the app. All this vital data streams to the clinician portal. Providers gain clinically relevant insights. They proactively tailor treatments. This significantly elevates the standard of patient care.
The platform accelerates clinician workflows. It significantly reduces the administrative burden. It decreases the number of required clinic visits. This eases critically long waiting lists for vestibular therapists. It supports overstretched healthcare teams globally. Patients benefit from continuous feedback and personalized adjustments. This direct communication fosters improved adherence. It leads to better treatment outcomes. Successful vestibular rehabilitation depends on consistent, accurate effort between visits. Vertigenius precisely enables this crucial aspect of recovery.
The United States represents a lucrative market. It has an addressable market exceeding €3 billion. Over 5,000 vestibular clinics operate nationwide. Vertigenius launched commercially in the US last October. It secured FDA registration prior to launch. Early adoption is strong. Twenty clinics in 11 US states use the device. These clinics have treated nearly 3,000 patients combined.
A key driver in the US is insurance reimbursement. Clinics can access additional income streams. This comes from remote therapeutic monitoring (RTM) codes. Vertigenius is specifically designed for RTM workflows. It captures vital non-physiological data. This includes detailed exercise adherence logs. It also records patient-reported symptoms. This comprehensive data supports RTM documentation and subsequent claims. It opens previously unavailable revenue opportunities for providers. This makes the platform financially attractive for US clinics.
The recent funding round was led by Atlantic Bridge. Enterprise Ireland and several venture firms also supported it. This follows a €2.1 million fundraising round in 2024. The new capital will scale US commercial operations. It will advance product development. The focus includes clinician workflow acceleration. Patient adherence improvements are also a priority.
Vertigenius will expand its US commercial team. New hires are planned for Ireland. These roles span clinical research, product R&D, quality assurance, and regulatory affairs. All new hires will operate from the company's Irish headquarters. The company anticipates further expansion. Europe is next. Then Asia Pacific and other global markets. Vertigenius aims to transform vertigo treatment worldwide.
Vertigenius addresses a significant, unmet clinical need. It targets a multi-billion-dollar market. Its unique platform fundamentally enhances vestibular care delivery. It continuously connects clinicians and patients. This vital support bridges the gap between visits. The early traction in the US validates the platform's clinical efficacy. It confirms the substantial commercial opportunity. The company actively recruits early adopter clinics and health systems. Its Lighthouse Site Program offers comprehensive onboarding and support. Participants contribute structured feedback. They may also join case studies and educational programs. Vertigenius is poised for substantial, transformative growth. It promises a new era in remote vertigo care management.